Intervals Between PCV13 and PPSV23 Vaccines: Recommendations of the Advisory Committee on Immunization Practices (ACIP).
Two pneumococcal vaccines are currently licensed for use in the United States: the 13-valent pneumococcal conjugate vaccine (PCV13 [Prevnar 13, Wyeth Pharmaceuticals, Inc., a subsidiary of Pfizer Inc.]) and the 23-valent pneumococcal polysaccharide vaccine (PPSV23 [Pneumovax 23, Merck and Co., Inc.]). The Advisory Committee on Immunization Practices (ACIP) currently recommends that a dose of PCV13 be followed by a dose of PPSV23 in all adults aged ≥65 years who have not previously received pneumococcal vaccine and in persons aged ≥2 years who are at high risk for pneumococcal disease because of underlying medical conditions (Table) (1-4). The recommended intervals between PCV13 and PPSV23 given in series differ by age and risk group and the order in which the two vaccines are given (1-4).
Miwako
M
Kobayashi
Nancy M
NM
Bennett
Ryan
R
Gierke
Olivia
O
Almendares
Matthew R
MR
Moore
Cynthia G
CG
Whitney
Tamara
T
Pilishvili
D000293:Adolescent; D000328:Adult; D026683:Advisory Committees; D000367:Age Factors; D000368:Aged; D002648:Child; D002675:Child, Preschool; D006801:Humans; D007115:Immunization Schedule; D008875:Middle Aged; D011008:Pneumococcal Infections / Q000517:prevention & control*; D022242:Pneumococcal Vaccines / Q000008:administration & dosage*; D017410:Practice Guidelines as Topic; D012307:Risk Factors; D014481:United States; D018074:Vaccines, Conjugate / Q000008:administration & dosage; D055815:Young Adult
C538862:13-valent pneumococcal vaccine; C414006:23-valent pneumococcal capsular polysaccharide vaccine; D022242:Pneumococcal Vaccines; D018074:Vaccines, Conjugate